Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group

NCT02343406 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02343406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02343406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
February 17, 2015
Completion date
June 24, 2019
Enrollment
266 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma